Zoetis Inc.(ZTS)

New York Stock Exchange
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Zoetis Inc. logo

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Latest News & Analysis

Zoetis (ZTS) Analysis: Avian flu vaccine, strategic focus on high-margin segments, strong dividend growth, and overall financial health.
Mar 26, 2025

Zoetis (ZTS): Vaccine, High-Margin Focus, and Dividends

Analysis of Zoetis (ZTS): Avian flu vaccine impact, strategic shift to high-margin segments, dividend growth, and financial health assessment.

Read more →
Zoetis stock analysis: Animal health market insights, Avian Influenza Vaccine impact, and financial health assessment for investors in 2025.
Mar 13, 2025

Zoetis (ZTS) Stock Analysis: Vaccine Impact, Financial Health, and Market Outlook

Comprehensive analysis of Zoetis Inc. (ZTS) in 2025: financial health, vaccine impact, and market outlook. Key insights from CFO Wetteny Joseph included.

Read more →
Zoetis stock analysis: Avian flu vaccine approval, market volatility, and long-term growth outlook for ZTS. Insights on financial performance and analyst expectations.
Feb 28, 2025

Zoetis (ZTS): Navigating Volatility with Avian Flu Vaccine and Long-Term Growth

Zoetis Inc. (ZTS) navigates market volatility with Avian Flu vaccine approval and long-term growth strategies. Q4 earnings, analyst ratings, and dividend policy analyzed.

Read more →
Zoetis (ZTS) Stock Analysis: Insights on market volatility, avian influenza vaccine, and growth strategies in animal health. Stay informed on ZTS stock performance.
Feb 27, 2025

Zoetis (ZTS) Analysis: Navigating Market Volatility

Analyzing Zoetis' (ZTS) recent performance, avian flu vaccine approval, and market outlook. A comprehensive look at the animal health giant's challenges and opportunities.

Read more →
Zoetis (ZTS) Stock Analysis: Avian Flu Vaccine, Earnings, and Growth Outlook for Investors
Feb 26, 2025

Zoetis (ZTS): Avian Flu Vaccine, Earnings Analysis, 2025 Outlook

Zoetis (ZTS) faces mixed Q4 earnings, avian flu vaccine progress, and competitive pressures. Analysis reveals key insights for investors.

Read more →
Zoetis stock analysis: avian flu vaccine, analyst ratings, and long-term growth prospects in the animal health market. ZTS stock.
Feb 25, 2025

Zoetis (ZTS): Avian Flu Vaccine, Analyst Ratings, and Long-Term Growth

Zoetis (ZTS) faces mixed Q4 results and analyst downgrades, yet avian flu vaccine approval and long-term growth potential offer a compelling investment case.

Read more →
Zoetis stock analysis: Avian flu vaccine approval impact on ZTS, analyst ratings, and investment opportunities in animal health.
Feb 24, 2025

Zoetis (ZTS): Avian Flu Vaccine Approval and Analyst Concerns

Zoetis (ZTS) faces analyst downgrades despite earnings beat, but USDA vaccine approval offers hope. Our report covers risks, competition, and key insights.

Read more →
Zoetis avian flu vaccine: Protecting poultry health and market stability.
Feb 21, 2025

Zoetis' Avian Flu Vaccine Gains USDA Approval: Analysis

Zoetis secures a conditional USDA license for its avian flu vaccine amid strong Q4 earnings but cautious 2025 guidance.

Read more →